Učitavanje...
A Fast and Clean BTK Inhibitor
Bruton’s tyrosine kinase (BTK) is a major drug target for B-cell related malignancies; however, existing BTK inhibitors approved for cancer treatment have significant off-targets that limit their use for autoimmune and inflammatory diseases. Remibrutinib (LOU064) is a novel covalent BTK inhibitor th...
Spremljeno u:
| Izdano u: | J Med Chem |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Chemical
Society
2020
|
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7304894/ https://ncbi.nlm.nih.gov/pubmed/32401033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.0c00597 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|